1. Home
  2. Live Updates
  3. Ryan deschner

Ryan Deschner News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ryan deschner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ryan Deschner Today - Breaking & Trending Today

Ardelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Call Transcript

Ardelyx, Inc. beats earnings expectations. Reported EPS is $-0.11, expectations were $-0.13. Ardelyx, Inc. ....

Mike Raab , Roanna Ruiz , Justin Renz , Ryan Deschner , Bunny Carter , Chris Raymond , Yigal Nochomovitz , Raymond James , Piper Sandler , Louise Chen , Susan Rodriguez , Caitlin Lowie , Mike Rob , Ardelyx Inc , Corporate Communications , Call Transcript May , Ardelyx First Quarter , Vice President , Investor Relations , Chief Commercial Officer , Chief Financial , Operations Officer , Ardelyx Assist , Highest Student Loan Debt , Outdoor Business Ideas , Dennis Ding ,

Analyst Highlights 'Rock Solid' Data For Vera Therapeutics' Kidney Disease-Targeted Atacicept, Upgrades To Strong Buy - Vera Therapeutics (NASDAQ:VERA)

72-week data from Vera Therapeutics' Phase 2b ORIGIN trial on atacicept for IgA nephropathy. Analysts upgrade stock to Strong Buy, citing impressive efficacy and low-risk profile. ....

Ryan Deschner , Steven Seedhouse , Raymond James , Vera Pharma , Vera Therapeutics , Strong Buy ,

What's Going On With Vera Therapeutics Stock Today? - Vera Therapeutics (NASDAQ:VERA)

Vera Therapeutics' significant market movements! Discover the latest on atacicept in IgA nephropathy trials, analyst ratings, and FDA approvals. ....

Laura Chico , Ryan Deschner , Steven Seedhouse , Raymond James , Vera Therapeutics , Strong Buy , Calliditas Therapeutics ,

Vera Therapeutics' Kidney Disease Drug Has Opportunity In A Competitive Development Landscape: Analyst - Vera Therapeutics (NASDAQ:VERA)

Raymond James initiated coverage on Vera Therapeutics Inc (NASDAQ: VERA), a late-stage drug developer in the autoimmune kidney space. The lead asset, atacicept, is a BLyS/APRIL dual inhibitor fusion protein currently in a Phase 3 study in IgA Nephropathy (IgAN). ....

Raymond James , Steven Seedhouse , Ryan Deschner , Vera Therapeutics Inc , Iga Nephropathy , Vera Therapeutics ,

Patient Demand Drives Ardelyx's Constipation Drug Success Amid IBS-C Treatment Gap, Says Analyst - Ardelyx (NASDAQ:ARDX)

Raymond James initiated coverage of Ardelyx Inc (NASDAQ: ARDX), noting the company's two early-stage launches underway for the same molecule with differentiated pricing: ....

Ryan Deschner , Steven Seedhouse , Raymond James , Ardelyx Inc , Strong Buy ,